No impact of disease duration on response to tildrakizumab treatment among patients with moderate-to-severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies

Johannes Griss, Gudrun Ratzinger, Julia Tatjana Maul, Wolfgang Weger, Diamant Thaçi, José Manuel Carrascosa, Constanze Jonak*

*Corresponding author for this work
Original languageEnglish
Article numbere263
JournalSkin Health and Disease
Issue number5
Publication statusPublished - 10.2023

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)
  • Centers: Center for Research on Inflammation of the Skin (CRIS)

DFG Research Classification Scheme

  • 205-19 Dermatology

Cite this